Phase I study of anti-PlGF monoclonal antibody (mAb) RO5323441 (RO) and anti-VEGF mab bevacizumab (BV) in patients with recurrent glioblastoma (GBM).
Ulrik Niels Lassen
No relevant relationships to disclose
Oliver L. Chinot
Consultant or Advisory Role - Roche
Honoraria - AstraZeneca; MSD; Roche
Research Funding - Merck; Roche
Catherine McBain
No relevant relationships to disclose
Morten Sorensen
Other Remuneration - Roche
Vibeke Andree Larsen
No relevant relationships to disclose
Maryline Barrie
No relevant relationships to disclose
Patrick Roth
Consultant or Advisory Role - MSD; Roche
Oliver Krieter
Employment or Leadership Position - Roche
Stock Ownership - Roche
Karen Wang
Employment or Leadership Position - Roche
Kai Habben
Employment or Leadership Position - Roche
Jean Tessier
Employment or Leadership Position - Roche
Angelika Lahr
Employment or Leadership Position - Roche
Matt Whiley
Employment or Leadership Position - Roche
Stock Ownership - Roche
Michael Weller
Consultant or Advisory Role - Antisense Pharma; Merck; Roche